Refine by
Neuroscience Articles & Analysis
132 news found
Creative Peptides, a biotech supplier of peptide specialities, is pleased to announce its participation at Neuroscience 2024, one of the most anticipated conferences in the field of neuroscience. Creative Peptides will showcase its cutting-edge products and services at booth #351. Neuroscience 2024 will be held at the McCormick Place Convention ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into ...
"Our SIM service is designed to meet the needs of researchers in various fields, including cell biology, neuroscience, and drug discovery." For more information about Creative Biostructure's Structured Illumination Microscopy service, please visit https://www.creative-biostructure.com/structured-illumination-microscopy-service.htm. ...
The applications of 5mC/5hmC sequencing are incredibly diverse and span various domains, including: Cancer Research: The understanding of 5mC and 5hmC distribution in cancer cells can illuminate the mechanisms underlying tumorigenesis, offering new avenues for the treatment of cancer. Neuroscience: The exploration of the roles played by 5mC and 5hmC in neurodevelopment and ...
” Animal cognitive behavioral tests aim to make significant strides in both animal cognition and behavioral neuroscience, opening the door for potential applications in comparative psychology, evolutionary biology, and neurodegenerative disease research. ...
He will continue to play a key role in driving the company’s research and development strategy as the company delivers its next generation of transformative neurotechnology innovations to the neuroscience research community. EMOTIV is a recognized pioneer and market leader in the field of neurotechnology and is backed and trusted by the scientific, academic, engineering, ...
“With Teva’s strong foundation in neuroscience and our in-house expertise in neurology and psychiatry, this licensing and collaboration agreement adds a promising new compound to our early-stage pipeline as a possible orphan disease treatment for the growing patient population living with multiple system atrophy, as well as a potential option for patients living with ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at the Society for ...
Institut Guttmann (Badalona); Heidelberg University Hospital (Heidelberg), Asepeyo Hospital (Sant Cugat); CEN (European Center of Neurosciences) (Madrid); Vall d’Hebron Hospital (Barcelona); SIRN (Barcelona); Isidre Esteve Foundation (Sant Cugat); National Hospital for Paraplegics (Toledo); Association of Multiple Sclerosis and other neurological diseases (Toledo). ...
Coralville, Iowa December 7, 2022 — Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – is a recipient of CB Insights’ fourth-annual Digital Health 150. The list recognizes the 150 most promising private digital health companies of 2022. “From reimagining clinical care, to leveraging tech like AR/VR to improve ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s ...
(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. ...
Antonella Santuccione Chadha Digital Phenotypes of Brain Diseases - Transforming neuroscience clinical development HBA Roche Event Round table: The missing X Speaker: Dr. ...
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA. ...
BySTALICLA
STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. ...
BySTALICLA
STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of ...
BySTALICLA
"We are really excited to be able to study this new treatment option for patients in the ADDRESS trial – it may offer new hope to those with uncontrolled epilepsy," stated Professor Mark Cook, Chair of Medicine and Director of Neurosciences at St. Vincent's Hospital in Melbourne, Australia. Refractory epilepsy, referred to as uncontrolled, intractable, or drug-resistant ...